

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2020/227549 A8

(43) International Publication Date
12 November 2020 (12.11.2020)

(51) International Patent Classification:

A61P 5/14 (2006.01) C07D 403/14 (2006.01)
C07D 401/14 (2006.01) A61K 31/53 (2006.01)
C07D 403/12 (2006.01)

ven NV, Gaston Greenslaan, 3001 Leuven (Heverlee) (BE).
MCGOWAN, David; Av de Biolley 80, 1150 Brussels
(BE). **DEVAL, Jerome**; 1131 Columbus Street, El Grana-
da, California 94018 (US).

(21) International Application Number:

PCT/US2020/031904

(74) Agent: **SCHORR, Kristel** et al.; Foley & Lardner LLP,
3000 K Street N. W., Suite 600, Washington, District of Co-
lumbia 20007-5109 (US).

(22) International Filing Date:

07 May 2020 (07.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/845,252	08 May 2019 (08.05.2019)	US
62/944,052	05 December 2019 (05.12.2019)	US
63/005,661	06 April 2020 (06.04.2020)	US

(71) Applicant: **ALIGOS THERAPEUTICS, INC.** [US/US];
1 Corporate Drive, 2nd Floor, South San Francisco, Califor-
nia 94080 (US).

(72) Inventors: **VANDYCK, Koen**; Deurnestraat 74, 3583
Beringen (BE). **RABOISSON, Pierre, Jean-Marie,**
Bernard; c/o Aligos Therapeutics, Inc., Bio-Incubator Leu-

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,


(54) Title: MODULATORS OF THR- β AND METHODS OF USE THEREOF

FIG. 1

(57) Abstract: Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

(I) TL-L₂-CE-HD

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

27 May 2021 (27.05.2021)

(15) Information about Correction:

see Notice of 27 May 2021 (27.05.2021)